Correction: Synthesis and antibacterial action of 3’,6’-disubstituted spectinomycins
Related Articles
Origin and de novo domestication of sweet orange
Sweet orange is cultivated worldwide but suffers from various devastating diseases because of its monogenetic background. The elucidation of the origin of a crop facilitates the domestication of new crops that may better cope with new challenges. Here we collected and sequenced 226 citrus accessions and assembled telomere-to-telomere phased diploid genomes of sweet orange and sour orange. On the basis of a high-resolution haplotype-resolved genome analysis, we inferred that sweet orange originated from a sour orange × mandarin cross and confirmed this model using artificial hybridization experiments. We identified defense-related metabolites that potently inhibited the growth of multiple industrially important pathogenic bacteria. We introduced diversity to sweet orange, which showed wide segregation in fruit flavor and disease resistance and produced canker-resistant sweet orange by selecting defense-related metabolites. Our findings elucidate the origin of sweet orange and de novo domesticated disease-resistant sweet oranges, illuminating a strategy for the rapid domestication of perennial crops.
Photothermal sensitive nanocomposite hydrogel for infectious bone defects
Infectious bone defects represent a substantial challenge in clinical practice, necessitating the deployment of advanced therapeutic strategies. This study presents a treatment modality that merges a mild photothermal therapy hydrogel with a pulsed drug delivery mechanism. The system is predicated on a hydrogel matrix that is thermally responsive, characteristic of bone defect sites, facilitating controlled and site-specific drug release. The cornerstone of this system is the incorporation of mild photothermal nanoparticles, which are activated within the temperature range of 40–43 °C, thereby enhancing the precision and efficacy of drug delivery. Our findings demonstrate that the photothermal response significantly augments the localized delivery of therapeutic agents, mitigating systemic side effects and bolstering efficacy at the defect site. The synchronized pulsed release, cooperated with mild photothermal therapy, effectively addresses infection control, and promotes bone regeneration. This approach signifies a considerable advancement in the management of infectious bone defects, offering an effective and patient-centric alternative to traditional methods. Our research endeavors to extend its applicability to a wider spectrum of tissue regeneration scenarios, underscoring its transformative potential in the realm of regenerative medicine.
Exploration of vanoxerine analogues as antibacterial agents
Mycobacterium tuberculosis is a bacterial pathogen, responsible for approximately 1.3 million deaths in 2022 through tuberculosis infections. The complex treatment regimen required to treat tuberculosis and growing rates of drug resistance, necessitates the development of new anti-mycobacterial agents. One approach is to repurpose drugs from other clinical applications. Vanoxerine (GBR 12909) was previously shown to have anti-mycobacterial activity, through dissipating the membrane electric potential and hence, cellular energetics. Several vanoxerine analogues were synthesised in this study, which exhibited a range of activities against mycobacteria and enterococcus. All active analogues had similar impacts on the membrane electric potential and inhibition of ethidium bromide efflux. The most active compound displayed reduced inhibitory activity against the known human target of vanoxerine, the dopamine transporter. This work has identified a promising analogue, which could provide a starting point for further medicinal chemistry and drug development efforts to target mycobacteria.
Successes and failures of conservation actions to halt global river biodiversity loss
To address the losses of river biodiversity worldwide, various conservation actions have been implemented to promote recovery of species and ecosystems. In this Review, we assess the effectiveness of these actions globally and regionally, and identify causes of success and failure. Overall, actions elicit little improvement in river biodiversity, in contrast with reports from terrestrial and marine ecosystems. This lack of improvement does not necessarily indicate a failure of any individual action. Rather, it can be attributed in part to remaining unaddressed stressors driving biodiversity loss; a poor match between the spatial scale of action and the scale of the affected area; and absence of adequate monitoring, including insufficient timescales, missing reference and control sites or insufficient selection of targeted taxa. Furthermore, outcomes are often not reported and are unevenly distributed among actions, regions and organism groups. Expanding from local-scale actions to coordinated, transformative, catchment-scale management approaches shows promise for improving outcomes. Such approaches involve identifying major stressors, appropriate conservation actions and source populations for recolonization, as well as comprehensive monitoring, relevant legislation and engaging all stakeholders to promote the recovery of river biodiversity.
Blue benzoquinone from scorpion venom shows bactericidal activity against drug-resistant strains of the priority pathogen Acinetobacter baumannii
Antibiotic-resistant bacteria pose a significant global health threat, particularly pathogens resistant to last-resort antibiotics, such as those listed as priority pathogens by the World Health Organization. Addressing this challenge requires the development of novel antimicrobial agents. Previously, we identified a blue 1,4-benzoquinone isolated from the venom of the Mexican scorpion Diplocentrus melici as a potent antimicrobial compound effective against Staphylococcus aureus and Mycobacterium tuberculosis. Moreover, we devised a cost-effective synthetic route for its production. In this study, we demonstrate that the blue benzoquinone exhibits antibacterial activity against additional pathogens, including the priority pathogen Acinetobacter baumannii. Notably, the compound effectively killed clinical strains of A. baumannii resistant to multiple antibiotics, including carbapenem and colistin. Furthermore, A. baumannii did not develop resistance to the benzoquinone even after multiple growth cycles under sub-inhibitory concentrations, unlike the tested antibiotics. These findings underscore the potential of this blue benzoquinone as a lead compound for the development of a new class of antibiotics targeting multidrug-resistant bacteria.
Responses